Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B ... for moderate to severe plaque psoriasis, and Ipsen’s Decapeptyl ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

The various types and presentations of psoriasis are outlined below. The commonest form of psoriasis is plaque psoriasis in which patients may have sharply circumscribed, round-oval, or nummular (coin ...

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.